Eli Lilly Stock-Based Compensation 2012-2026 | LLY
Eli Lilly annual/quarterly stock-based compensation history and growth rate from 2012 to 2026. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Eli Lilly stock-based compensation for the quarter ending March 31, 2026 was $626M, a 3.04% decline year-over-year.
- Eli Lilly stock-based compensation for the twelve months ending March 31, 2026 was $1.608B, a 4.22% decline year-over-year.
- Eli Lilly annual stock-based compensation for 2025 was $0.626B, a 3.04% decline from 2024.
- Eli Lilly annual stock-based compensation for 2024 was $0.646B, a 2.72% increase from 2023.
- Eli Lilly annual stock-based compensation for 2023 was $0.629B, a 69.36% increase from 2022.
|
Eli Lilly Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2025 | $626 |
| 2024 | $646 |
| 2023 | $629 |
| 2022 | $371 |
| 2021 | $343 |
| 2020 | $308 |
| 2019 | $312 |
| 2018 | $280 |
| 2017 | $281 |
| 2016 | $255 |
| 2015 | $218 |
| 2014 | $156 |
| 2013 | $145 |
| 2012 | $142 |
| 2011 | $147 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $887.629B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |